ArticleJournal of gastroenterology and hepatology2025
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis.
Article in Journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Aspirin for hepatocellular carcinoma prevention in MASLD: How far are we ready to proceed?: Editorial on "Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis".Clinical and molecular hepatology · 2026Article
- Correspondence to editorial 1 on "Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis".Clinical and molecular hepatology · 2026Article
- Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis.Clinical and molecular hepatology · 2026Article
- Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis.Journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
aimsThe use of aspirin in hepatocellular carcinoma (HCC) prevention and the risk of gastrointestinal (GI) bleeding is still uncertain in patients with hepatitis B virus (HBV)-related cirrhosis. We investigated the association between aspirin use and the risks of HCC and GI bleeding in patients with HBV-related cirrhosis.
methodsWe conducted a 3-year landmark analysis using nationwide cohort data from the National Health Insurance Service of South Korea. Patients diagnosed with compensated HBV-related cirrhosis in 2005-2017 were included. Patients who were prescribed aspirin for at least 90 days consecutively during the 3-year exposure period were classified as the aspirin-treated group. The risks of HCC and GI bleeding were estimated in a cohort matched by propensity scores.
resultsDuring a median of 7.6 years of follow-up, the 10-year cumulative incidence of HCC was 41.8% among aspirin users (n = 608) and 46.5% among nonusers (n = 2432) (p = 0.033). The aspirin-treated group showed a significantly lower risk of HCC than the untreated group (adjusted hazard ratio [aHR] = 0.84, 95% confidence interval [CI] = 0.73-0.96; p = 0.013). The 10-year cumulative incidence of GI bleeding was 29.5% among aspirin users and 24.0% among nonusers (p = 0.016). The aspirin-treated group showed a significantly higher risk of GI bleeding than the untreated group (aHR = 1.20, 95% CI = 1.02-1.42; p = 0.029).
conclusionsIn patients with HBV-related cirrhosis, the aspirin-treated group showed a significantly lower risk of HCC than the untreated group, whereas the risk of GI bleeding was significantly higher in the aspirin-treated group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.